Celera Genomics and Lynx announce two new agreements
The first agreement involves the integration of Lynx's high-resolution gene expression data, derived from normal human tissues analyzed using Lynx's MPSS technology, into Celera's database products for distribution to it's customers through the Celera Discovery System (CDS). Under the terms of the second agreement, Lynx will apply its MPSS technology to perform additional gene expression analyses for Celera and help supplement the Lynx database offering.
In addition, Celera intends to apply its bioinformatics expertise to analyze Lynx's high-resolution gene expression data and to design and develop software tools to view and distribute the related information on CDS. Celera will use Lynx to create a body atlas of gene expression data.
"We are delighted to be commercializing through Celera the body of human genomic information we produce using our MPSS technology," said Norrie Russell, President and CEO of Lynx. "In addition to the scientific interest in such data, we hope to expand on the commercial interest and demand for our products and services through working with a collaborator of the power and excellence of Celera."
"This agreement between Celera and Lynx is an example of the ways that Celera is looking to enhance the utility of our genomics and related biological data sets," said Peter Barrett, Executive Vice President and CBO of Celera. "With Lynx we believe we can supplement our internal discovery capabilities, as well as those of our customers, with the addition of the MPSS technology."